Comparison of [ 18F]FDG uptake and distribution with hypoxia and proliferation in FaDu human squamous cell carcinoma (hSCC) xenografts after single dose irradiation

International Journal of Radiation Biology

Volumn 85, Issue 9, 2009, Pages 772-780

  Bruechner, Kerstin ^a,e   Bergmann, Ralf ^b,e   Santiago, Alina ^a,e   Mosch, Birgit ^b   Yaromina, Ala ^a,e   Hessel, Franziska ^a,e   Hofheinz, Frank ^c   Van Den Hoff, Joerg ^b,e   Baumann, Michael ^a,d,e   Beuthien Baumann, Bettina ^a,b,e  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^c ABX Advanced Biochemical Compounds   (Germany)

^d Experimental Centre

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

FDG; Human tumour xenografts; Hypoxia; Positron emission tomography; Proliferation; Single dose irradiation

Indexed keywords

BROXURIDINE; FLUORODEOXYGLUCOSE F 18; PIMONIDAZOLE; DIAGNOSTIC AGENT; GLUCOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HYPOPHARYNX CARCINOMA; HYPOXIA; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; TUMOR NECROSIS; TUMOR XENOGRAFT; WHOLE BODY RADIATION; ANIMAL; CELL HYPOXIA; CELL PROLIFERATION; COMPARATIVE STUDY; HUMAN; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; RADIATION EXPOSURE; SCINTISCANNING; TIME; TRANSPORT AT THE CELLULAR LEVEL; XENOGRAFT;

MUS; MUS MUSCULUS;

ANIMALS; AUTORADIOGRAPHY; BIOLOGICAL TRANSPORT; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CELL PROLIFERATION; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MICE; MICE, NUDE; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 70249134563     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.1080/09553000903043067     Document Type: Article

References (32)

1. Abe Y, Matsuzawa T, Fujiwara T, Fukuda H, Itoh M, Yamada K, Yamaguchi K, Sato T, Ido T. 1986. Assessment of radio-therapeutic effects on experimental tumours using 18F-2-fluoro-2-deoxy-D-glucose. European Journal of Nuclear Medicine 12:325-328.
2. Abe Y, Matsuzawa T, Fujiwara T, Itoh M, Fukuda H, Yamaguchi K, Kubota K, Hatazawa J, Tada M, Ido T, et al. 1990. Clinical assessment of therapeutic effects on cancer using 18F-2-fluoro-2-deoxy-D-glucose and positron emission tomography: Preliminary study of lung cancer. International Journal of Radiation Oncology, Biology, Physics 19:1005-1010.
3. Baumann M, Krause M, Hill R. 2008. Exploring the role of cancer stem cells in radioresistance. Nature Reviews Cancer 8:545-554.
4. Bentzen L, Keiding S, Horsman M, Falborg L, Hansen S, Overgaard J. 2000. Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography - a study evaluating [18F]Fluoro-2-deoxy-D-glucose. Acta Oncologica 39:629-637.
5. Beuthien-Baumann B, Gabrys D, Wüllrich K, Hofheinz F, Krause M, Bergmann R, Hessel F, Yaromina A, Eicheler W, Baumann M. 2006. Impact of tumour hypoxia on the FDG uptake in two human tumour models on nude mice investigated with PET, autoradiography and functional histology. Radiotherapy and Oncology 81:S142.
6. Brown R, Fisher S, Wahl R. 1993. Autoradiographic evaluation of the intra-tumoral distribution of 2-deoxy-D-glucose and monoclonal antibodies in xenografts of human ovarian adeno-carcinoma. Journal of Nuclear Medicine 34:75-82.
7. Clavo A, Brown R, Wahl R. 1995. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. Journal of Nuclear Medicine 36:1625-1632.
8. Dearling J, Flynn A, Sutcliffe-Goulden J, Petrie I, Boden R, Green A, Boxer G, Begent R, Pedley R. 2004. Analysis of the regional uptake of radiolabeled deoxyglucose analogs in human tumor xenografts. Journal of Nuclear Medicine 45:101-107.
9. De Wit M, Raabe A, Seegers B, Buchert R, Beck-Bornholdt H-P, Alberti W, Hossfeld D. 2004. Time benefit in the assessment of recurrences following fractionated radiotherapy in an experimental tumour system using positron-emission tomography with 18F-fluorodeoxyglucose. International Journal of Radiation Biology 80:529-539.
10. Dierckx R, Van De Wiele C. 2008. FDG uptake, a surrogate of tumour hypoxia? European Journal of Nuclear Medicine and Molecular Imaging 35:1544-1549.
11. Füchtner F, Steinbach J, Mäding P, Johannsen B. 1996. Basic hydrolysis of 2-[18F]Fluoro-1,3,4,6-tetra-O-acetyl-D-glucose in the preparation of 2-[18F]Fluoro-2-deoxy-D-glucose. Applied Radiation and Isotopes 47:61-66.
12. Gillies R, Robey I, Gatenby R. 2008. Causes and consequences of increased glucose metabolism of cancers. Journal of Nuclear Medicine 49(Suppl. 2):24-42.
13. Gray L, Conger A, Ebert M, Hornsey S, Scott O. 1953. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. The British Journal of Radiology 26:638-648.
14. Hautzel H, Muller-Gartner H. 1997. Early changes in fluorine-18-FDG uptake during radiotherapy. Journal of Nuclear Medicine 38:1384-1386.
15. Hoskin P, Sibtain A, Daley F, Saunders M, Wilson G. 2004. The immunohistochemical assessment of hypoxia, vascularity and proliferation in bladder carcinoma. Radiotherapy and Oncology 72:159-168.
16. Ichiya Y, Kuwabara Y, Otsuka M, Tahara T, Yoshikai T, Fukumura T, Jingu K, Masuda K. 1991. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. Journal of Nuclear Medicine 32:1655-1660.
17. Keyes J. 1995. SUV: Standard uptake or silly useless value? Journal of Nuclear Medicine 36:1836-1839.
18. Koritzinsky M, Wouters B, Amellem O, Pettersen E. 2001. Cell cycle progression and radiation survival following prolonged hypoxia and re-oxygenation. International Journal of Radiation Biology 77:319-328.
19. Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. 1994. Active and passive mechanisms of [fluorine-18] fluor-odeoxyglucose uptake by proliferating and prenecrotic cancer cells in vivo: A microautoradiographic study. Journal of Nuclear Medicine 35:1067-1075.
20. Macheda M, Rogers S, Best J. 2005. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. Journal of Cellular Physiology 202:654-662.
21. Plathow C, Weber W. 2008. Tumor cell metabolism imaging. Journal of Nuclear Medicine 49(Suppl. 2):43-63.
22. Pugachev A, Ruan S, Carlin S, Larson S, Campa J, Ling C, Humm J. 2005. Dependence of FDG uptake on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics 62:545-553.
23. Rege S, Safa A, Chaiken L, Hoh C, Juillard G, Withers H. 2000. Positron emission tomography: An independent indicator of radiocurability in head and neck carcinomas. American Journal of Clinical Oncology 23:164-169.
24. Reske S, Kotzerke J. 2001. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, 'Onko-PET III', 21 July and 19 September 2000. European Journal of Nuclear Medicine 28:1707-1723.
25. Schreiber A, Krause M, Zips D, Dorfler A, Richter K, Vettermann S, Petersen C, Beuthien-Baumann B, Thummler D, Baumann M. 2004. Effect of the hypoxic cell sensitizer isometronidazole on local control of two human squamous cell carcinomas after fractionated irradiation. Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics 180:375-382.
26. Schuetze C, Bergmann R, Mosch B, Yaromina A, Hessel F, Krause M, Thames H, Zips D, Maeding P, Baumann M, Beuthien-Baumann B. 2008. Pre-treatment FMISO hypoxic volume is a significant prognostic factor for local control after irradiation of FaDu HNSCC xenografts. Radiotherapy and Oncology 88:S102.
27. Schuetze C, Bergmann R, Yaromina A, Hessel F, Kotzerke J, Steinbach J, Baumann M, Beuthien-Baumann B. 2007. Effect of increase of radiation dose on local control relates to pretreatment FDG uptake in FaDu tumours in nude mice. Radiotherapy and Oncology 83:311-315.
28. Sugiyama M, Sakahara H, Sato K, Harada N, Fukumoto D, Kakiuchi T, Hirano T, Kohno E, Tsukada H. 2004. Evaluation of 30-deoxy-30-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. Journal of Nuclear Medicine 45:1754-1758.
29. Tanaka T, Furukawa T, Fujieda S, Kasamatsu S, Yonekura Y, Fujibayashi Y. 2006. Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models. Nuclear Medicine and Biology 33:743-750.
30. Thews O, Kelleher D, Vaupel P. 2003. Lack of association between tumor oxygenation and cell cycle distribution or proliferation kinetics in experimental sarcomas. Advances in Experimental Medicine and Biology 540:245-250.
31. Yaromina A, Zips D, Thames HD, Eicheler W, Krause M, Rosner A, Haase M, Petersen C, Raleigh JA, Quennet V, Walenta S, Mueller-Klieser W, Baumann M. 2006. Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: The need for a multivariate approach in biomarker studies. Radiotherapy and Oncology 81:122-129.
32. Zolzer F, Streffer C. 2002. Increased radiosensitivity with chronic hypoxia in four human tumor cell lines. International Journal of Radiation Oncology, Biology, Physics 54:910-920.